Skip to content
  • Friday, 14 August 2026
  • 8:26 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • The Eliquis Patent Cliff: A $14.2 Billion Revenue Erosion Set to Reshape Pharmaceutical Giants
Pharmaceutical R&D

The Eliquis Patent Cliff: A $14.2 Billion Revenue Erosion Set to Reshape Pharmaceutical Giants

Teuku Ryan May 27, 2026 0

The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…

Read More
Pharmaceutical R&D

Eliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic Proportions

Teuku Ryan May 1, 2026 0

The pharmaceutical industry is bracing for one of the most significant patent cliff events in its history as Eliquis, the…

Read More
Innovative Spin-Polarized Fuel Mix Could Revolutionize Fusion Efficiency and Pave the Way for Compact Power PlantsMapping the Inflammatory Landscape of the Bone Marrow Microenvironment in the Early Stages of Myeloid MalignancyMacau Approves ImmunityBio’s Anktiva for Bladder Cancer, Marking First Asian Regulatory MilestoneCan the heart heal itself? New study says it can
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ